Brief: Mei Pharma Announces First Patient Dosed In Clinical Study Evaluating Me-344 Plus Bevacizumab (Avastin) In Patients With Previously Treated Metastatic Colorectal Cancer
16/08/2023 13:18
Aug 16 (Reuters) - Mei Pharma Inc MEIP.O :
* MEI PHARMA ANNOUNCES FIRST PATIENT DOSED IN CLINICAL STUDY
EVALUATING ME-344 PLUS BEVACIZUMAB (AVASTIN®) IN PATIENTS WITH
PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER
* ANTICIPATES ANNOUNCING SAFETY AND EFFICACY DATA FROM FIRST
COHORT OF 20 ME-344 PATIENTS IN FIRST HALF OF 2024
* ANTICIPATES ANNOUNCING SAFETY AND EFFICACY DATA FROM FIRST
COHORT OF 20 ME-344 PATIENTS IN FIRST HALF OF 2024
Source text for Eikon: ID:nBw5ywNYwa
Further company coverage: MEIP.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Lite Strategy
See all newsBrief: Lite Strategy Receives Governance Rights And Option To Buy Litvm Future Network Tokens
U.S. RESEARCH ROUNDUP- Equinix, KLA, WW Grainger
Brief: Lite Strategy Inc - On Nov 14, Board Approves Justin J. File As Permanent CEO - SEC Filing
Brief: Lite Strategy Reports First Quarter Fiscal Year 2026 Results Highlights Successful Launch Of $100M Litecoin Treasury Strategy And Movement Into Active Capital Market Operations
Brief: Lite Strategy Announces $25M Share Repurchase Program, Signaling Shift From Initial Litecoin Accumulation To Active Capital Market Operations